Opticrom

Selected form

Sodium Cromoglycate

Method of action: Drugs For Obstructive Airway Diseases, Ophthalmologicals

Treatment option: Allergic Conjunctivitis, Rhinitis, Pink Eye

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Opticrom

What is Opticrom?

Opticrom is a therapeutic eye drop solution primarily used to manage and relieve the symptoms of allergic conjunctivitis. It is formulated to address ocular inflammation and irritation caused by various allergens, such as pollen, pet dander, or dust mites.

Therapeutic Class and Mechanism

The active ingredient in Opticrom is sodium cromoglicate, which belongs to a class of medications known as mast cell stabilizers. Unlike antihistamines that counteract the effects of histamine after it has been released, mast cell stabilizers work by preventing the release of histamine and other inflammatory mediators from mast cells in the eye.

When the eyes are exposed to allergens, mast cells can become sensitized and rupture. By stabilizing the membrane of these cells, the medication helps to prevent the subsequent allergic response, including itching, redness, and swelling.

Common Indications

Opticrom is commonly used for several types of allergic eye conditions:

Acute Allergic Conjunctivitis: Temporary inflammation caused by sudden exposure to an allergen.
Seasonal Allergic Conjunctivitis (Hay Fever): Recurring symptoms that appear during specific times of the year when pollen counts are high.
Perennial Allergic Conjunctivitis: Year-round symptoms often triggered by indoor allergens like mold or animal fur.
Vernal Keratoconjunctivitis: A more chronic and severe form of seasonal eye allergy.

Composition and Appearance

Opticrom typically presents as a clear, colorless to pale yellow aqueous solution. It is designed for topical application directly to the surface of the eye. While the primary component is sodium cromoglicate, the solution may also contain purified water and specific excipients to maintain the correct acidity and tonicity, ensuring the solution is compatible with the natural environment of the human eye.

What side effects are possible with Opticrom?

Possible Side Effects and Safety Information

The safety profile of Opticrom (cromolyn sodium ophthalmic solution) is primarily defined by effects localized to the eye, with minimal systemic absorption documented in official regulatory labeling. Adverse events are formally structured by regulatory authorities according to frequency and the body system affected.

Official Adverse Reaction Listings and Frequency

Based on official prescribing information, the most frequently reported adverse reactions are associated with the administration process itself and are generally transient:

Frequency Classification	System-Organ Class (SOC)	Adverse Reaction
Common	Eye disorders	Ocular stinging, burning, or irritation upon instillation.
Uncommon	Eye disorders	Conjunctival injection (redness), dryness, transient visual blurring.
Rare	Immune system disorders	Hypersensitivity reactions (e.g., immediate allergic reactions).
Rare	Nervous system disorders	Headache.

These classifications indicate that the medicine's risk profile is dominated by minor, temporary, localized effects. The most common reactions are explicitly noted in regulatory documents as occurring immediately upon application.

Serious Reactions and Population Safety

Serious Adverse Reactions Anaphylactic reactions and generalized hypersensitivity are classified as rare but serious events associated with this medication in regulatory texts. These events represent the highest level of systemic risk documented.

Population-Specific Safety Notes Official labeling documents affirm that cromolyn sodium ophthalmic solution can be used safely in pediatric patients (including children below two years of age) and older adults. No specific dose adjustments or unique safety concerns for individuals with renal impairment or hepatic impairment are mandated in the official prescribing information for the ophthalmic formulation, reflecting minimal systemic exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Opticrom (Sodium Cromoglycate ophthalmic solution) indicates that systemic overdose is considered very unlikely. This assessment is based on the drug's pharmacokinetic profile, which shows minimal absorption from the ocular surface and poor absorption from the gastrointestinal tract if the solution is accidentally ingested. Regulatory agencies note that there have been no specific reported cases of overdosage, and consequently, no distinct systemic signs, symptoms, or life-threatening outcomes have been documented in official product labeling.

Should an overdose be suspected, including through accidental ingestion of the eye drop solution, government guidance mandates that the individual contact a poison control center or seek an emergency room immediately for professional management. If excess drops have been put in the eye, the only specific instruction for immediate action is to rinse the eyes with clean water at room temperature.

Management of a suspected overdose is typically limited to medical observation and the provision of supportive or symptomatic treatment as needed. Immediate emergency services are required if the affected individual exhibits severe signs such as collapse, seizure activity, difficulty breathing, or inability to be awakened, as these may indicate a severe medical event requiring urgent intervention as stated by the regulator.

Therapeutic Uses of Opticrom

Quick Facts

Relief for symptoms associated with seasonal allergic conjunctivitis.
May be used for certain chronic allergic eye conditions.
Aids in the management of specific inflammatory eye disorders like vernal keratoconjunctivitis.

What Opticrom Treats: Main Uses and Benefits

Opticrom (cromolyn sodium ophthalmic solution) is utilized to manage the ocular signs and symptoms that often occur with allergic conjunctivitis. This includes conditions like seasonal allergic conjunctivitis (often referred to as hay fever of the eyes), which presents with reactions to common environmental allergens such as pollen.

The medication supports the temporary relief of a range of eye-related allergic symptoms. These symptoms may encompass itching, eye watering, redness, and the general discomfort associated with allergic exposure. The product may also be beneficial in the management of other persistent allergic eye conditions and specific inflammatory disorders of the eye, including vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

The therapeutic application of this medication focuses on addressing the eye manifestations of various allergies. Individuals with these conditions may experience reduced discomfort and a better quality of life through the consistent use of this treatment, as part of an overall health plan.

Regulatory References

FDA regulatory information on Cromolyn Sodium Ophthalmic Solution

Eligibility and Restrictions for Use

The eligibility for using Opticrom (cromolyn sodium ophthalmic solution) is determined by specific rules documented in official regulatory labeling, defining permitted, restricted, and prohibited populations.

Contraindications and Restrictions

Population Status	Regulatory Rule	Reason for Restriction
Contraindicated	Patients with known hypersensitivity to cromolyn sodium or any other ingredient in the formulation.	Absolute non-eligibility based on ingredient component sensitivity.
Conditional Use	Individuals who wear soft contact lenses.	The lenses must be removed before instillation and may not be reinserted until a specified time has passed, due to the presence of a preservative.

Age and Physiological Eligibility

Children: Safety and effectiveness are established for children aged 4 years and older. Use in children below the age of 4 years has not been established in official labeling.
Adults and Older Adults: Use is permitted and established, with no specific restrictions or required dosage adjustments documented for the geriatric population.
Pregnancy: The medication is categorized as Pregnancy Category B by the FDA. Regulatory guidelines state it should be used only if clearly needed, reflecting limited systemic absorption and a lack of adequate human studies.
Lactation: Caution must be exercised when administered to a nursing woman, as it is unknown whether the active ingredient is excreted in human milk.

Regulators have not specified any mandatory eligibility limitations for the ophthalmic solution based on hepatic or renal impairment, due to the very low degree of systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Opticrom (cromolyn sodium ophthalmic solution) is primarily governed by its minimal systemic absorption. Due to the very small amount of drug that enters the bloodstream, the risk of clinically significant systemic drug-drug interactions with oral or injectable medications is considered negligible.

Documented Interaction Considerations

Interaction Type	Official Regulatory Statement
Systemic Pharmacokinetic	No known or expected interactions with systemic medications (e.g., CYP enzymes, transporters).
Local Pharmacodynamic	Concomitant use of ophthalmic corticosteroids is generally permissible. Caution is advised when combining with other anti-allergy eye drops to manage potential additive local effects.

Procedural and Local Constraints

Official labeling emphasizes constraints related to administration and local ocular exposure rather than drug metabolism.

Other Ophthalmic Medications: A time separation rule is required when administering Opticrom with other eye drops or eye ointments. Doses must typically be spaced by at least five to fifteen minutes to prevent interference and ensure proper drug coverage.
Contact Lenses: Due to the presence of the preservative benzalkonium chloride, soft contact lenses must be removed prior to application and should not be reinserted until at least fifteen minutes after use to avoid discoloration and potential irritation.

Mechanism of Action

Mast Cell Membrane Stabilization: Influence on Immediate Release

Opticrom (cromolyn sodium) acts as a stabilizer of the mast cell membrane, which serves as the primary cellular target. This mechanism involves interfering with the calcium ion influx required for the intracellular process of degranulation. By modulating this early step, the drug reduces the rapid discharge of chemical messengers before they exit the cell.

Reducing Inflammatory Mediator Signaling

This stabilization mechanism results in the reduction of mediator release, including signaling molecules like histamine and leukotrienes. By acting on these initial steps in the cellular signaling cascade, the drug modifies the molecular events that influence downstream cellular effects. This process reduces the signal input for subsequent physiological events.

Mechanism and Localized Physiological Effect

The resulting physiological consequence is a reduction in the magnitude of the localized tissue response. This mechanism operates peripherally, targeting signaling patterns characteristic of the immediate cellular response and supporting a reduction in the overall inflammatory load at the site of application.

Dosage and Administration Information

Administration Guidelines for Opticrom

The usage of Opticrom (Sodium Cromoglycate ophthalmic solution) focuses on a precise topical delivery to the ocular surface. The medication is designed for application in a divided-dose frequency pattern and must be administered strictly at regular intervals throughout the day.

Dosage and Timing Protocol

The typical administration regimen involves instilling 1 or 2 drops into each affected eye. This is repeated four to six times daily, with the efficacy of the treatment being dependent upon this necessary consistency. Because the medication is intended to prevent the allergic cascade, therapy must be initiated prophylactically—ideally before exposure to known allergens—and continued continuously throughout the entire allergy season to sustain the intended effect. While the initial response may be noted within a few days, treatment may be required for up to six weeks to establish full therapeutic control.

Procedural and Age-Based Rules

The procedural constraints are centered on maintaining product sterility and proper application. Prior to instillation, soft contact lenses must be removed, and the dropper tip must not contact the eye or any surface to prevent contamination. The product is approved for use in adults and is extended to the pediatric population 4 years of age and older, with safety and effectiveness not established below this minimum age. Once the bottle is opened, any remaining solution must be discarded after 4 weeks, regardless of the contents remaining.

Recent Clinical Evidence

Research evidence / Overview of studies for Opticrom

Evidence for Use in Seasonal Allergic Conjunctivitis (SAC)

The core research base for Opticrom (Sodium Cromoglycate) for conditions characterized by fluctuating or episodic manifestations, such as seasonal allergic conjunctivitis, includes short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving unstable symptoms and have been consolidated through Systematic Reviews and Meta-analyses. Research explored how symptoms change over time in populations of adults and adolescents with known seasonal allergies. In these trials, researchers primarily monitored outcomes related to physical discomfort, tracking symptoms like itching, redness, and the recorded usage of rescue medication. Systematic reviews have described patterns in measurements across many of the included studies. Comparative evidence is lacking against newer topical therapies, and there is limited information for long-term outcomes.

Evidence for Use in Chronic Allergic Eye Conditions

Opticrom was also studied for conditions involving periods of heightened symptoms that are more persistent, such as Vernal Keratoconjunctivitis (VKC). The research structure involves a mix of smaller-scale RCTs and long-term Observational Studies, which were used for monitoring over defined time intervals in both pediatric and adult populations. Studies monitored outcomes capturing phases of heightened symptom activity, such as tracking the frequency of severe flare-ups. Findings describe the reported experience of patients regarding their daily functioning while facing these long-term conditions. Due to the rarity of these conditions, the research base often has modest sample sizes, and there is a greater reliance on observational data for understanding the long-term course of symptoms.

What Remains Uncertain and Areas for Future Research

The evidence landscape presents several research limitation frames. Certainty remains low in areas related to long-term outcomes for the general allergic population, as the pivotal trials were often short-term. Additionally, data for certain groups remain insufficient; for instance, there is limited research providing context on patients with underlying comorbidities or very elderly populations. Research does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes.

Key Studies & References

Label: CROMOLYN SODIUM solution/ drops (Ophthalmic Solution, USP 4%) - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Opticrom (FAQ)

Q: How does Opticrom's mechanism of action differ from other common allergy eye drops?

Official product information indicates that Opticrom's active ingredient, sodium cromoglycate, works as a mast cell stabilizer. This means it acts to stabilize mast cells, which interferes with the release of inflammatory chemicals, such as histamine. This differs from some other common allergy eye drops, such as antihistamines, which are primarily designed to block the effects of histamine that has already been released in the eye.

Q: Does the benzalkonium chloride preservative in Opticrom cause any eye irritation?

Official labeling documents state that the preservative benzalkonium chloride (BAC), an ingredient in this medicine, has been associated with eye irritation. As an excipient with a known effect, BAC can also potentially affect the tear film and the surface of the eye. This is one reason why soft contact lenses must be removed before using the drops.

Q: Is Opticrom available over-the-counter (OTC) or only by prescription?

In many regions, the ophthalmic solution containing sodium cromoglycate is typically categorized as a prescription-only medication. Official labeling does not support its general availability for purchase over-the-counter (OTC).

Q: What happens if I stop using Opticrom suddenly during allergy season?

The official product information emphasizes that Opticrom is intended for continuous and regular use throughout the allergy season. As this medication is designed for the prevention of symptoms, abruptly discontinuing its use may lead to the return of allergic symptoms, as the preventative effect may cease.

Q: Can I use Opticrom with other types of contact lenses, such as rigid gas permeable (RGP) lenses?

Official product information indicates that the general recommendation is to avoid wearing contact lenses (including both soft and rigid gas permeable lenses) while using this medication for the treatment of certain eye conditions. This guidance is in place to reduce the risk of further irritation or contamination.

How should Opticrom be stored and disposed of?

Storage and Disposal of Opticrom (Cromolyn Sodium Ophthalmic Solution)

Opticrom must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from light and not frozen. The container must be kept tightly closed and stored out of the sight and reach of children.

Stability and Packaging

Container Type	Post-Opening Stability Limit
Multi-Dose Bottle	Discard four weeks after first opening
Single-Dose Container	Must be used immediately and discarded after use

Disposal Requirements

Unused or expired Opticrom must not be disposed of via wastewater or household waste. Disposal must be carried out in accordance with local requirements, and patients should consult a pharmacist for guidance on discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.